Article

Opioid Prescriptions Alarming Among COPD Patients

Author(s):

Study raises safety concerns about chronic obstructive pulmonary disease patients’ use of opioids at high rates.

Researchers from St. Michael’s Hospital in Toronto, Canada, are raising safety concerns about chronic obstructive pulmonary disease (COPD) patients’ use of opioids at high rates, citing their findings published in the British Journal of Clinical Pharmacology.

The researchers reviewed healthcare administrative data from more than 120,000 COPD patients in order to describe the scope, pattern, and participant characteristics of patients who engage in incident opioid use. The patients had physician confirmed COPD and were 66-years-old or older. They were not receiving palliative care. The study authors examined the incidence of oral opioid receipt between April 1, 2003 and March 31, 2012, as well as various patterns of incident opioid use.

About three quarters of patients who were living on their own were given new opioid prescriptions over the study period, and 55% of patients living in long term care centers received new opioid prescriptions throughout the same period. The researchers concluded that COPD patients, especially those living in long-term care centers, were potentially at risk for using excessive opioids. Those patients were given multiple opioid prescriptions, early refills, and prescriptions that lasted more than 30 days, they said.

“The new use of opioids was remarkably high among adults with COPD living in the community,” corresponding author Nicholas Vozoris, MHSc, MD, a respirologist at St. Michael’s Hospital, explained in a press release. “The amount of opioid use is concerning given this is an older population, and older adults are more sensitive to narcotic side effects.”

The researchers hypothesized that adult COPD patients might receive opioids, such as codeine, oxycodone, and morphine, more frequently to treat muscle pain, breathlessness, and insomnia. Side effects of these drugs include falls and fractures, confusion, memory impairment, fatigue, constipation, nausea, vomiting, and abdominal pain.

Even though patients may be looking for quick fixes, Vozoris said, physicians might believe that narcotics are the solution for COPD symptoms. The majority of opioid prescriptions came from family physicians. A majority of the new prescriptions were a mixture of opioids and non-opioids, like Percocet, Endocet, and Lenoltec.

“Patients and prescribers should reflect on the way narcotics are being used in this older and respiratory vulnerable population,” concluded Vozoris. “They should be more careful about when narcotics are used and how they’re being used.”

Related Videos
How to Manage Aspirin-Exacerbated Respiratory Disease
Safety Data on Dupilumab, Ensifentrine for COPD, with MeiLan Han, MD
MeiLan Han, MD: Discussing Updates on Dupilumab, Ensifentrine in 2025 GOLD Report
Christian Sadaka, MD: Significant Increase in Pediatric Gastroparesis Hospital Admissions After COVID-19
How Artificial Intelligence is Being Used in Lung Imaging, with Rachel Eddy, PhD
Developing Risk Assessment Tools for Viruses in School
Using Microbiomes to Diagnose Ventilator-Associated Pneumonia
What Do Patients Need to Learn About their Hypersensitivity Pneumonitis?
© 2024 MJH Life Sciences

All rights reserved.